Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2231392A
- Development stage
- Phase 2
- Lead developer
- University of Oxford
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK2231392A is an investigational adjuvanted hepatitis B vaccine developed by GSK. It consists of the recombinant hepatitis B surface antigen (HBsAg) combined with the AS01B adjuvant system. The AS01B adjuvant is a liposome-based system containing two immunostimulants: 3-O-desacyl-4'-monophosphoryl lipid A (MPL), which acts as a Toll-like receptor 4 (TLR4) agonist, and the saponin QS-21. This vaccine is designed to enhance the immune response, particularly in populations that may not respond well to standard hepatitis B vaccines, such as older adults or immunocompromised individuals. Clinical trials have utilized GSK2231392A to characterize the kinetics of early and adaptive immune responses, including T-cell and B-cell activation, in healthy hepatitis B virus-naive adults.
- Other names
- HBsAg/AS01B vaccineAS01B-adjuvanted hepatitis B vaccineAS-01B-adjuvanted hepatitis B vaccineAS 01B-adjuvanted hepatitis B vaccineHBsAg/AS01B
02
Targets
HBsAg (Hepatitis B surface antigen)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on GSK2231392A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2231392A.